This year, the conference was held for the first time in online form and brought together more than 1,000 representatives of companies instead of the conventional 500 guests. The guests of the conference are representatives of political and economic circles.
The participants discussed new ways to develop the Russian-German partnership, paid attention to the development of the Russian market, and identified opportunities to improve the Russia’s investment image in Germany.
The panel discussion “Russia – innovations in the pharmaceutical industry” was attended by Vladimir Khristenko, President of NANOLEK, and Philip Romanov (Head of the Department of State Regulation of Pharmaceuticals, Ministry of Health of the Russian Federation), Svetlana Gerbel (CEO at Siemens Healthineers Russia), Christian Macke (member of the Board at Berlin-Chemie AG), Miguel Pagan Fernandez, Chief Technology Officer at Stada.
The participants discussed the promotion of innovations in the pharmaceutical industry, which was one of the first to embrace changes caused by the pandemic. Vladimir Khristenko drew attention to the fact that innovations in the pharmaceutical industry are developing in 3 directions. First of all, it is the production of vaccines and medicines, and the pandemic has accelerated this process. Secondly, it’s an unprecedented production upscaling, when you need to produce several tens of billions of vaccine doses per year in a record time. This is an enormous challenge for manufacturers of equipment, auxiliary materials, and warehouses. Thirdly, innovations in the regulatory system which had to look for solutions to meet the challenge with appropriate speed.
Vladimir Khristenko answered the moderator’s question about the partnership: “Since its foundation, NANOLEK has built its development on international partnership, while resting upon the “win-win” paradigm. You need to join forces to achieve the best results together, and NANOLEK offers first-class production and access to the Russian market. Our capabilities are constantly growing: thanks to the events happened in last year, we revised our development strategy and highlighted 3 main areas: vaccines, specialty therapies, and contract manufacturing, and we plan to greatly concentrate on R&D as well.”